Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab

74
9
Favorite

Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab

The Straits Times2021-06-30

SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（9）

Yongstonio
·2021-06-30
Good job
Reply
1
Report
henryg
·2021-06-30
That's great
Reply
1
Report
SaveHK
·2021-06-30
Yes buy first before other jump in. Buy low lah if can can SELL High..haha???
Reply
1
Report
Fold Replies
- iHuat:
  Good
  2021-06-30
  Reply
  Report
Armuaayu
·2021-06-30
Thanks for sharing
Reply
1
Report
edgetrader
·2021-06-30
Reopening soon
Reply
Like
Report
szueyann
·2021-06-30
Please like and comment. Thanks
Reply
2
Report
Fold Replies
- Lcc73:
  Comment
  2021-06-30
  Reply
  Report
Tunaaa
·2021-06-30
Oh
Reply
4
Report
Dirui
·2021-06-30
Like pls.
Reply
6
Report
Fold Replies
- Tunaaa:
  Got it
  2021-06-30
  Reply
  Report
YuanYuan888
·2021-06-30
Huat
Reply
3
Report
Fold Replies
- Dirui:
  Gd
  2021-06-30
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2147689312?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-30 09:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2147689312","market":"us","top_or_hot":-1,"title":"Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab","media":"The Straits Times","content":"<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Source Link</a>\n\n</div>\n","source":"straits_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore inks deal with GSK to purchase Covid-19 drug sotrovimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 09:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab","article_id":"2147689312","we_media_id":null,"thumbnails":[],"rights":{"source":"straits_highlight","url":"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab","rn_cache_url":null,"customStyle":"","selectors":"body","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2147689312","pubTimestamp":1625015157,"sourceInfo":{"source_id":"straits_highlight","name":"Straits Times"},"weMediaInfo":null,"summary":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore","collect":0,"end_time":0,"defaultTopTitle":"straitstimes.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK":"葛兰素史克"},"translate_title":"新加坡墨水公司与葛兰素史克收购新冠肺炎药物索托维单抗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":0.9},"content_text":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients with mild to moderate Covid-19.\nThe advance purchase agreement is for the supply of sotrovimab, an investigational single-dose monoclonal antibody administered through intravenous infusion, GSK Singapore said in a statement on Wednesday (June 29).\nIt is used to treat Covid-19 patients who do not need supplemental oxygen but are at risk of progressing to severe disease.\nSotrovimab is currently undergoing regulatory review by the Health Sciences Authority for interim authorisation under the Pandemic Special Access Route (PSAR), GSK Singapore said.\nThe medication was, on May 26, granted emergency-use authorisation by the United States Food and Drug Administration; the European Medicines Agency's Committee for Medicinal Products for Human Use has also issued a positive scientific opinion.\nThe British drugmaker's PSAR application includes data from an interim analysis of efficacy and safety data from its phase three trial, which it said was stopped early by an independent data-monitoring committee in March due to evidence of \"profound clinical efficacy\".\n\"Results of the interim analysis, based on data from 583 randomised patients, demonstrated an 85 per cent reduction in hospitalisation or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial,\" GSK Singapore said.\nIt noted that the PSAR review will also consider the medicine's quality and safety data, adding that final results from its efficacy trial will be available later this year.\nPreclinical data has suggested that sotromivab targets a conserved epitope of the Sars-CoV-2 spike protein, which is less likely to mutate over time, GSK said.\nDr Phil Pang, chief medical officer of Vir, said the treatment appears to \"retain activity against all circulating variants of concern\", including the highly transmissible Delta variant which originated from India, based on data from several in vitro studies.\nMr Mike Crichton, senior vice-president for speciality and primary-care therapy area at GSK, said vaccines, together with treatments like sotrovimab, have the potential to increase the chance of ending the pandemic, as variants of the coronavirus continue to arise.\nGSK and Vir are in discussions with other governments to explore similar supply agreements, as countries accelerate their vaccine and therapeutics programmes against Covid-19, the company said.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":153242479,"gmtCreate":1625029920491,"gmtModify":1703850530551,"author":{"id":"3569913551788820","authorId":"3569913551788820","authorIdStr":"3569913551788820","name":"Yongstonio","avatar":"https://static.tigerbbs.com/416ee5e99c5bc9b5db9e020ff2af415b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3569913551788820"},"htmlText":"Good job","listText":"Good job","text":"Good job","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153242479","repostId":2147689312,"repostType":4,"repost":{"id":"2147689312","pubTimestamp":1625015157,"share":"https://ttm.financial/m/news/2147689312?lang=&edition=fundamental","pubTime":"2021-06-30 09:05","market":"sg","language":"en","title":"Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2147689312","media":"The Straits Times","summary":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore","content":"<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore inks deal with GSK to purchase Covid-19 drug sotrovimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 09:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"source_url":"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147689312","content_text":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients with mild to moderate Covid-19.\nThe advance purchase agreement is for the supply of sotrovimab, an investigational single-dose monoclonal antibody administered through intravenous infusion, GSK Singapore said in a statement on Wednesday (June 29).\nIt is used to treat Covid-19 patients who do not need supplemental oxygen but are at risk of progressing to severe disease.\nSotrovimab is currently undergoing regulatory review by the Health Sciences Authority for interim authorisation under the Pandemic Special Access Route (PSAR), GSK Singapore said.\nThe medication was, on May 26, granted emergency-use authorisation by the United States Food and Drug Administration; the European Medicines Agency's Committee for Medicinal Products for Human Use has also issued a positive scientific opinion.\nThe British drugmaker's PSAR application includes data from an interim analysis of efficacy and safety data from its phase three trial, which it said was stopped early by an independent data-monitoring committee in March due to evidence of \"profound clinical efficacy\".\n\"Results of the interim analysis, based on data from 583 randomised patients, demonstrated an 85 per cent reduction in hospitalisation or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial,\" GSK Singapore said.\nIt noted that the PSAR review will also consider the medicine's quality and safety data, adding that final results from its efficacy trial will be available later this year.\nPreclinical data has suggested that sotromivab targets a conserved epitope of the Sars-CoV-2 spike protein, which is less likely to mutate over time, GSK said.\nDr Phil Pang, chief medical officer of Vir, said the treatment appears to \"retain activity against all circulating variants of concern\", including the highly transmissible Delta variant which originated from India, based on data from several in vitro studies.\nMr Mike Crichton, senior vice-president for speciality and primary-care therapy area at GSK, said vaccines, together with treatments like sotrovimab, have the potential to increase the chance of ending the pandemic, as variants of the coronavirus continue to arise.\nGSK and Vir are in discussions with other governments to explore similar supply agreements, as countries accelerate their vaccine and therapeutics programmes against Covid-19, the company said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153827171,"gmtCreate":1625018307493,"gmtModify":1703850216973,"author":{"id":"3581580167581733","authorId":"3581580167581733","authorIdStr":"3581580167581733","name":"henryg","avatar":"https://static.tigerbbs.com/8fedb3f88a534bff6452065d91213662","vip":1,"hat":"https://static.tigerbbs.com/6444b4970948c1077534c593eccd6d16","crmLevel":2,"crmLevelSwitch":1,"idStr":"3581580167581733"},"htmlText":"That's great&nbsp;","listText":"That's great&nbsp;","text":"That's great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153827171","repostId":2147689312,"repostType":4,"repost":{"id":"2147689312","pubTimestamp":1625015157,"share":"https://ttm.financial/m/news/2147689312?lang=&edition=fundamental","pubTime":"2021-06-30 09:05","market":"sg","language":"en","title":"Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2147689312","media":"The Straits Times","summary":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore","content":"<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore inks deal with GSK to purchase Covid-19 drug sotrovimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 09:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"source_url":"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147689312","content_text":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients with mild to moderate Covid-19.\nThe advance purchase agreement is for the supply of sotrovimab, an investigational single-dose monoclonal antibody administered through intravenous infusion, GSK Singapore said in a statement on Wednesday (June 29).\nIt is used to treat Covid-19 patients who do not need supplemental oxygen but are at risk of progressing to severe disease.\nSotrovimab is currently undergoing regulatory review by the Health Sciences Authority for interim authorisation under the Pandemic Special Access Route (PSAR), GSK Singapore said.\nThe medication was, on May 26, granted emergency-use authorisation by the United States Food and Drug Administration; the European Medicines Agency's Committee for Medicinal Products for Human Use has also issued a positive scientific opinion.\nThe British drugmaker's PSAR application includes data from an interim analysis of efficacy and safety data from its phase three trial, which it said was stopped early by an independent data-monitoring committee in March due to evidence of \"profound clinical efficacy\".\n\"Results of the interim analysis, based on data from 583 randomised patients, demonstrated an 85 per cent reduction in hospitalisation or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial,\" GSK Singapore said.\nIt noted that the PSAR review will also consider the medicine's quality and safety data, adding that final results from its efficacy trial will be available later this year.\nPreclinical data has suggested that sotromivab targets a conserved epitope of the Sars-CoV-2 spike protein, which is less likely to mutate over time, GSK said.\nDr Phil Pang, chief medical officer of Vir, said the treatment appears to \"retain activity against all circulating variants of concern\", including the highly transmissible Delta variant which originated from India, based on data from several in vitro studies.\nMr Mike Crichton, senior vice-president for speciality and primary-care therapy area at GSK, said vaccines, together with treatments like sotrovimab, have the potential to increase the chance of ending the pandemic, as variants of the coronavirus continue to arise.\nGSK and Vir are in discussions with other governments to explore similar supply agreements, as countries accelerate their vaccine and therapeutics programmes against Covid-19, the company said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153881636,"gmtCreate":1625017230825,"gmtModify":1703850180941,"author":{"id":"3570678493691973","authorId":"3570678493691973","authorIdStr":"3570678493691973","name":"SaveHK","avatar":"https://static.tigerbbs.com/89b74f5799a23844400ed6de94296d38","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3570678493691973"},"htmlText":"Yes buy first before other jump in. Buy low lah if can can SELL High..haha???","listText":"Yes buy first before other jump in. Buy low lah if can can SELL High..haha???","text":"Yes buy first before other jump in. Buy low lah if can can SELL High..haha???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153881636","repostId":2147689312,"repostType":4,"repost":{"id":"2147689312","pubTimestamp":1625015157,"share":"https://ttm.financial/m/news/2147689312?lang=&edition=fundamental","pubTime":"2021-06-30 09:05","market":"sg","language":"en","title":"Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2147689312","media":"The Straits Times","summary":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore","content":"<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore inks deal with GSK to purchase Covid-19 drug sotrovimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 09:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"source_url":"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147689312","content_text":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients with mild to moderate Covid-19.\nThe advance purchase agreement is for the supply of sotrovimab, an investigational single-dose monoclonal antibody administered through intravenous infusion, GSK Singapore said in a statement on Wednesday (June 29).\nIt is used to treat Covid-19 patients who do not need supplemental oxygen but are at risk of progressing to severe disease.\nSotrovimab is currently undergoing regulatory review by the Health Sciences Authority for interim authorisation under the Pandemic Special Access Route (PSAR), GSK Singapore said.\nThe medication was, on May 26, granted emergency-use authorisation by the United States Food and Drug Administration; the European Medicines Agency's Committee for Medicinal Products for Human Use has also issued a positive scientific opinion.\nThe British drugmaker's PSAR application includes data from an interim analysis of efficacy and safety data from its phase three trial, which it said was stopped early by an independent data-monitoring committee in March due to evidence of \"profound clinical efficacy\".\n\"Results of the interim analysis, based on data from 583 randomised patients, demonstrated an 85 per cent reduction in hospitalisation or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial,\" GSK Singapore said.\nIt noted that the PSAR review will also consider the medicine's quality and safety data, adding that final results from its efficacy trial will be available later this year.\nPreclinical data has suggested that sotromivab targets a conserved epitope of the Sars-CoV-2 spike protein, which is less likely to mutate over time, GSK said.\nDr Phil Pang, chief medical officer of Vir, said the treatment appears to \"retain activity against all circulating variants of concern\", including the highly transmissible Delta variant which originated from India, based on data from several in vitro studies.\nMr Mike Crichton, senior vice-president for speciality and primary-care therapy area at GSK, said vaccines, together with treatments like sotrovimab, have the potential to increase the chance of ending the pandemic, as variants of the coronavirus continue to arise.\nGSK and Vir are in discussions with other governments to explore similar supply agreements, as countries accelerate their vaccine and therapeutics programmes against Covid-19, the company said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5076351,"gmtCreate":1625020537514,"gmtModify":1663230316141,"authorId":3577604413370961,"author":{"id":3577604413370961,"authorId":3577604413370961,"name":"iHuat","avatar":"https://static.tigerbbs.com/ba908ea2f329e3dce63ffec884debf23","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153881636,"type":1,"supId":0,"prevId":0,"content":"Good ","text":"Good ","html":"Good "}],"langContent":"EN"},{"id":153816209,"gmtCreate":1625016950301,"gmtModify":1703850169423,"author":{"id":"3580096275862714","authorId":"3580096275862714","authorIdStr":"3580096275862714","name":"Armuaayu","avatar":"https://static.tigerbbs.com/7c44c5239106e492558d407f0d742cfb","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3580096275862714"},"htmlText":"Thanks for sharing&nbsp;","listText":"Thanks for sharing&nbsp;","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153816209","repostId":2147689312,"repostType":4,"repost":{"id":"2147689312","pubTimestamp":1625015157,"share":"https://ttm.financial/m/news/2147689312?lang=&edition=fundamental","pubTime":"2021-06-30 09:05","market":"sg","language":"en","title":"Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2147689312","media":"The Straits Times","summary":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore","content":"<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore inks deal with GSK to purchase Covid-19 drug sotrovimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 09:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"source_url":"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147689312","content_text":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients with mild to moderate Covid-19.\nThe advance purchase agreement is for the supply of sotrovimab, an investigational single-dose monoclonal antibody administered through intravenous infusion, GSK Singapore said in a statement on Wednesday (June 29).\nIt is used to treat Covid-19 patients who do not need supplemental oxygen but are at risk of progressing to severe disease.\nSotrovimab is currently undergoing regulatory review by the Health Sciences Authority for interim authorisation under the Pandemic Special Access Route (PSAR), GSK Singapore said.\nThe medication was, on May 26, granted emergency-use authorisation by the United States Food and Drug Administration; the European Medicines Agency's Committee for Medicinal Products for Human Use has also issued a positive scientific opinion.\nThe British drugmaker's PSAR application includes data from an interim analysis of efficacy and safety data from its phase three trial, which it said was stopped early by an independent data-monitoring committee in March due to evidence of \"profound clinical efficacy\".\n\"Results of the interim analysis, based on data from 583 randomised patients, demonstrated an 85 per cent reduction in hospitalisation or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial,\" GSK Singapore said.\nIt noted that the PSAR review will also consider the medicine's quality and safety data, adding that final results from its efficacy trial will be available later this year.\nPreclinical data has suggested that sotromivab targets a conserved epitope of the Sars-CoV-2 spike protein, which is less likely to mutate over time, GSK said.\nDr Phil Pang, chief medical officer of Vir, said the treatment appears to \"retain activity against all circulating variants of concern\", including the highly transmissible Delta variant which originated from India, based on data from several in vitro studies.\nMr Mike Crichton, senior vice-president for speciality and primary-care therapy area at GSK, said vaccines, together with treatments like sotrovimab, have the potential to increase the chance of ending the pandemic, as variants of the coronavirus continue to arise.\nGSK and Vir are in discussions with other governments to explore similar supply agreements, as countries accelerate their vaccine and therapeutics programmes against Covid-19, the company said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153810546,"gmtCreate":1625016794385,"gmtModify":1703850161665,"author":{"id":"3570751249933438","authorId":"3570751249933438","authorIdStr":"3570751249933438","name":"edgetrader","avatar":"https://static.tigerbbs.com/7d0e920d94a7891f4c6393f3e5510ccc","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3570751249933438"},"htmlText":"Reopening soon","listText":"Reopening soon","text":"Reopening soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153810546","repostId":2147689312,"repostType":4,"repost":{"id":"2147689312","pubTimestamp":1625015157,"share":"https://ttm.financial/m/news/2147689312?lang=&edition=fundamental","pubTime":"2021-06-30 09:05","market":"sg","language":"en","title":"Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2147689312","media":"The Straits Times","summary":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore","content":"<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore inks deal with GSK to purchase Covid-19 drug sotrovimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 09:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"source_url":"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147689312","content_text":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients with mild to moderate Covid-19.\nThe advance purchase agreement is for the supply of sotrovimab, an investigational single-dose monoclonal antibody administered through intravenous infusion, GSK Singapore said in a statement on Wednesday (June 29).\nIt is used to treat Covid-19 patients who do not need supplemental oxygen but are at risk of progressing to severe disease.\nSotrovimab is currently undergoing regulatory review by the Health Sciences Authority for interim authorisation under the Pandemic Special Access Route (PSAR), GSK Singapore said.\nThe medication was, on May 26, granted emergency-use authorisation by the United States Food and Drug Administration; the European Medicines Agency's Committee for Medicinal Products for Human Use has also issued a positive scientific opinion.\nThe British drugmaker's PSAR application includes data from an interim analysis of efficacy and safety data from its phase three trial, which it said was stopped early by an independent data-monitoring committee in March due to evidence of \"profound clinical efficacy\".\n\"Results of the interim analysis, based on data from 583 randomised patients, demonstrated an 85 per cent reduction in hospitalisation or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial,\" GSK Singapore said.\nIt noted that the PSAR review will also consider the medicine's quality and safety data, adding that final results from its efficacy trial will be available later this year.\nPreclinical data has suggested that sotromivab targets a conserved epitope of the Sars-CoV-2 spike protein, which is less likely to mutate over time, GSK said.\nDr Phil Pang, chief medical officer of Vir, said the treatment appears to \"retain activity against all circulating variants of concern\", including the highly transmissible Delta variant which originated from India, based on data from several in vitro studies.\nMr Mike Crichton, senior vice-president for speciality and primary-care therapy area at GSK, said vaccines, together with treatments like sotrovimab, have the potential to increase the chance of ending the pandemic, as variants of the coronavirus continue to arise.\nGSK and Vir are in discussions with other governments to explore similar supply agreements, as countries accelerate their vaccine and therapeutics programmes against Covid-19, the company said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153895275,"gmtCreate":1625016415297,"gmtModify":1703850144269,"author":{"id":"3573721781255613","authorId":"3573721781255613","authorIdStr":"3573721781255613","name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573721781255613"},"htmlText":"Please like and comment. Thanks","listText":"Please like and comment. Thanks","text":"Please like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153895275","repostId":2147689312,"repostType":4,"repost":{"id":"2147689312","pubTimestamp":1625015157,"share":"https://ttm.financial/m/news/2147689312?lang=&edition=fundamental","pubTime":"2021-06-30 09:05","market":"sg","language":"en","title":"Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2147689312","media":"The Straits Times","summary":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore","content":"<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore inks deal with GSK to purchase Covid-19 drug sotrovimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 09:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"source_url":"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147689312","content_text":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients with mild to moderate Covid-19.\nThe advance purchase agreement is for the supply of sotrovimab, an investigational single-dose monoclonal antibody administered through intravenous infusion, GSK Singapore said in a statement on Wednesday (June 29).\nIt is used to treat Covid-19 patients who do not need supplemental oxygen but are at risk of progressing to severe disease.\nSotrovimab is currently undergoing regulatory review by the Health Sciences Authority for interim authorisation under the Pandemic Special Access Route (PSAR), GSK Singapore said.\nThe medication was, on May 26, granted emergency-use authorisation by the United States Food and Drug Administration; the European Medicines Agency's Committee for Medicinal Products for Human Use has also issued a positive scientific opinion.\nThe British drugmaker's PSAR application includes data from an interim analysis of efficacy and safety data from its phase three trial, which it said was stopped early by an independent data-monitoring committee in March due to evidence of \"profound clinical efficacy\".\n\"Results of the interim analysis, based on data from 583 randomised patients, demonstrated an 85 per cent reduction in hospitalisation or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial,\" GSK Singapore said.\nIt noted that the PSAR review will also consider the medicine's quality and safety data, adding that final results from its efficacy trial will be available later this year.\nPreclinical data has suggested that sotromivab targets a conserved epitope of the Sars-CoV-2 spike protein, which is less likely to mutate over time, GSK said.\nDr Phil Pang, chief medical officer of Vir, said the treatment appears to \"retain activity against all circulating variants of concern\", including the highly transmissible Delta variant which originated from India, based on data from several in vitro studies.\nMr Mike Crichton, senior vice-president for speciality and primary-care therapy area at GSK, said vaccines, together with treatments like sotrovimab, have the potential to increase the chance of ending the pandemic, as variants of the coronavirus continue to arise.\nGSK and Vir are in discussions with other governments to explore similar supply agreements, as countries accelerate their vaccine and therapeutics programmes against Covid-19, the company said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5075665,"gmtCreate":1625016780200,"gmtModify":1663230313744,"authorId":3564712937580301,"author":{"id":3564712937580301,"authorId":3564712937580301,"name":"Lcc73","avatar":"https://static.tigerbbs.com/72523840e673b42dada1978a1dc74033","vip":1,"currentWearingBadge":{"badgeId":"23f878ed27704312ae41c7f17e73b319-2","templateUuid":"23f878ed27704312ae41c7f17e73b319","name":"Annualised return","description":"Top 30%","bigImgUrl":"https://community-static.tradeup.com/news/50461c8139b6ca50fe2dae19aa769b25","smallImgUrl":"https://community-static.tradeup.com/news/c8eef504853d5a517c50d7a88fa5c1e1","grayImgUrl":"https://community-static.tradeup.com/news/5273727845028b8d9b65556bdcb217b9","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.16","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":5300},"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153895275,"type":1,"supId":0,"prevId":0,"content":"Comment","text":"Comment","html":"Comment"}],"langContent":"EN"},{"id":153802470,"gmtCreate":1625015969990,"gmtModify":1703850129353,"author":{"id":"3586991451337808","authorId":"3586991451337808","authorIdStr":"3586991451337808","name":"Tunaaa","avatar":"https://static.tigerbbs.com/ce153d45d93b437fb6713a9e09b459b7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586991451337808"},"htmlText":"Oh&nbsp;","listText":"Oh&nbsp;","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153802470","repostId":2147689312,"repostType":4,"repost":{"id":"2147689312","pubTimestamp":1625015157,"share":"https://ttm.financial/m/news/2147689312?lang=&edition=fundamental","pubTime":"2021-06-30 09:05","market":"sg","language":"en","title":"Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2147689312","media":"The Straits Times","summary":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore","content":"<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore inks deal with GSK to purchase Covid-19 drug sotrovimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 09:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"source_url":"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147689312","content_text":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients with mild to moderate Covid-19.\nThe advance purchase agreement is for the supply of sotrovimab, an investigational single-dose monoclonal antibody administered through intravenous infusion, GSK Singapore said in a statement on Wednesday (June 29).\nIt is used to treat Covid-19 patients who do not need supplemental oxygen but are at risk of progressing to severe disease.\nSotrovimab is currently undergoing regulatory review by the Health Sciences Authority for interim authorisation under the Pandemic Special Access Route (PSAR), GSK Singapore said.\nThe medication was, on May 26, granted emergency-use authorisation by the United States Food and Drug Administration; the European Medicines Agency's Committee for Medicinal Products for Human Use has also issued a positive scientific opinion.\nThe British drugmaker's PSAR application includes data from an interim analysis of efficacy and safety data from its phase three trial, which it said was stopped early by an independent data-monitoring committee in March due to evidence of \"profound clinical efficacy\".\n\"Results of the interim analysis, based on data from 583 randomised patients, demonstrated an 85 per cent reduction in hospitalisation or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial,\" GSK Singapore said.\nIt noted that the PSAR review will also consider the medicine's quality and safety data, adding that final results from its efficacy trial will be available later this year.\nPreclinical data has suggested that sotromivab targets a conserved epitope of the Sars-CoV-2 spike protein, which is less likely to mutate over time, GSK said.\nDr Phil Pang, chief medical officer of Vir, said the treatment appears to \"retain activity against all circulating variants of concern\", including the highly transmissible Delta variant which originated from India, based on data from several in vitro studies.\nMr Mike Crichton, senior vice-president for speciality and primary-care therapy area at GSK, said vaccines, together with treatments like sotrovimab, have the potential to increase the chance of ending the pandemic, as variants of the coronavirus continue to arise.\nGSK and Vir are in discussions with other governments to explore similar supply agreements, as countries accelerate their vaccine and therapeutics programmes against Covid-19, the company said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153802338,"gmtCreate":1625015942924,"gmtModify":1703850128860,"author":{"id":"3576728357666184","authorId":"3576728357666184","authorIdStr":"3576728357666184","name":"Dirui","avatar":"https://static.tigerbbs.com/028fdb43f6018331c0e01e03918d42c9","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3576728357666184"},"htmlText":"Like pls.&nbsp;","listText":"Like pls.&nbsp;","text":"Like pls.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153802338","repostId":2147689312,"repostType":4,"repost":{"id":"2147689312","pubTimestamp":1625015157,"share":"https://ttm.financial/m/news/2147689312?lang=&edition=fundamental","pubTime":"2021-06-30 09:05","market":"sg","language":"en","title":"Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2147689312","media":"The Straits Times","summary":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore","content":"<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore inks deal with GSK to purchase Covid-19 drug sotrovimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 09:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"source_url":"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147689312","content_text":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients with mild to moderate Covid-19.\nThe advance purchase agreement is for the supply of sotrovimab, an investigational single-dose monoclonal antibody administered through intravenous infusion, GSK Singapore said in a statement on Wednesday (June 29).\nIt is used to treat Covid-19 patients who do not need supplemental oxygen but are at risk of progressing to severe disease.\nSotrovimab is currently undergoing regulatory review by the Health Sciences Authority for interim authorisation under the Pandemic Special Access Route (PSAR), GSK Singapore said.\nThe medication was, on May 26, granted emergency-use authorisation by the United States Food and Drug Administration; the European Medicines Agency's Committee for Medicinal Products for Human Use has also issued a positive scientific opinion.\nThe British drugmaker's PSAR application includes data from an interim analysis of efficacy and safety data from its phase three trial, which it said was stopped early by an independent data-monitoring committee in March due to evidence of \"profound clinical efficacy\".\n\"Results of the interim analysis, based on data from 583 randomised patients, demonstrated an 85 per cent reduction in hospitalisation or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial,\" GSK Singapore said.\nIt noted that the PSAR review will also consider the medicine's quality and safety data, adding that final results from its efficacy trial will be available later this year.\nPreclinical data has suggested that sotromivab targets a conserved epitope of the Sars-CoV-2 spike protein, which is less likely to mutate over time, GSK said.\nDr Phil Pang, chief medical officer of Vir, said the treatment appears to \"retain activity against all circulating variants of concern\", including the highly transmissible Delta variant which originated from India, based on data from several in vitro studies.\nMr Mike Crichton, senior vice-president for speciality and primary-care therapy area at GSK, said vaccines, together with treatments like sotrovimab, have the potential to increase the chance of ending the pandemic, as variants of the coronavirus continue to arise.\nGSK and Vir are in discussions with other governments to explore similar supply agreements, as countries accelerate their vaccine and therapeutics programmes against Covid-19, the company said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5075496,"gmtCreate":1625015985135,"gmtModify":1663230315033,"authorId":3586991451337808,"author":{"id":3586991451337808,"authorId":3586991451337808,"name":"Tunaaa","avatar":"https://static.tigerbbs.com/ce153d45d93b437fb6713a9e09b459b7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153802338,"type":1,"supId":0,"prevId":0,"content":"Got it ","text":"Got it ","html":"Got it "}],"langContent":"EN"},{"id":153174782,"gmtCreate":1625015645946,"gmtModify":1703850117753,"author":{"id":"3586310832970658","authorId":"3586310832970658","authorIdStr":"3586310832970658","name":"YuanYuan888","avatar":"https://static.tigerbbs.com/25da6e75318c464e3fdb52ea1064e2cc","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586310832970658"},"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153174782","repostId":2147689312,"repostType":4,"repost":{"id":"2147689312","pubTimestamp":1625015157,"share":"https://ttm.financial/m/news/2147689312?lang=&edition=fundamental","pubTime":"2021-06-30 09:05","market":"sg","language":"en","title":"Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2147689312","media":"The Straits Times","summary":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore","content":"<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore inks deal with GSK to purchase Covid-19 drug sotrovimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 09:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"source_url":"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147689312","content_text":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients with mild to moderate Covid-19.\nThe advance purchase agreement is for the supply of sotrovimab, an investigational single-dose monoclonal antibody administered through intravenous infusion, GSK Singapore said in a statement on Wednesday (June 29).\nIt is used to treat Covid-19 patients who do not need supplemental oxygen but are at risk of progressing to severe disease.\nSotrovimab is currently undergoing regulatory review by the Health Sciences Authority for interim authorisation under the Pandemic Special Access Route (PSAR), GSK Singapore said.\nThe medication was, on May 26, granted emergency-use authorisation by the United States Food and Drug Administration; the European Medicines Agency's Committee for Medicinal Products for Human Use has also issued a positive scientific opinion.\nThe British drugmaker's PSAR application includes data from an interim analysis of efficacy and safety data from its phase three trial, which it said was stopped early by an independent data-monitoring committee in March due to evidence of \"profound clinical efficacy\".\n\"Results of the interim analysis, based on data from 583 randomised patients, demonstrated an 85 per cent reduction in hospitalisation or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial,\" GSK Singapore said.\nIt noted that the PSAR review will also consider the medicine's quality and safety data, adding that final results from its efficacy trial will be available later this year.\nPreclinical data has suggested that sotromivab targets a conserved epitope of the Sars-CoV-2 spike protein, which is less likely to mutate over time, GSK said.\nDr Phil Pang, chief medical officer of Vir, said the treatment appears to \"retain activity against all circulating variants of concern\", including the highly transmissible Delta variant which originated from India, based on data from several in vitro studies.\nMr Mike Crichton, senior vice-president for speciality and primary-care therapy area at GSK, said vaccines, together with treatments like sotrovimab, have the potential to increase the chance of ending the pandemic, as variants of the coronavirus continue to arise.\nGSK and Vir are in discussions with other governments to explore similar supply agreements, as countries accelerate their vaccine and therapeutics programmes against Covid-19, the company said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5075486,"gmtCreate":1625015950522,"gmtModify":1663230314849,"authorId":3576728357666184,"author":{"id":3576728357666184,"authorId":3576728357666184,"name":"Dirui","avatar":"https://static.tigerbbs.com/028fdb43f6018331c0e01e03918d42c9","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153174782,"type":1,"supId":0,"prevId":0,"content":"Gd","text":"Gd","html":"Gd"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":74,"commentSize":9,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}